Wedbush Maintains Neutral on Vor Biopharma, Raises Price Target to $27
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Wedbush analyst Martin Fan maintains Vor Biopharma (NASDAQ:VOR) with a Neutral and raises the price target from $18 to $27.
Wedbush analyst Martin Fan maintains Vor Biopharma (NASDAQ:VOR) with a Neutral and raises the price target from $18 to $27.